AU2002229141A1 - Hydrogel-driven drug dosage form - Google Patents

Hydrogel-driven drug dosage form

Info

Publication number
AU2002229141A1
AU2002229141A1 AU2002229141A AU2914102A AU2002229141A1 AU 2002229141 A1 AU2002229141 A1 AU 2002229141A1 AU 2002229141 A AU2002229141 A AU 2002229141A AU 2914102 A AU2914102 A AU 2914102A AU 2002229141 A1 AU2002229141 A1 AU 2002229141A1
Authority
AU
Australia
Prior art keywords
drug
water
dosage form
containing composition
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229141A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Walter C. Babcock
Ronald Arthur Beyerinck
Mark Brian Chidlaw
William John Curatolo
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2002229141A1 publication Critical patent/AU2002229141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002229141A 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form Abandoned AU2002229141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09
US60/224199 2000-08-09
PCT/IB2001/001390 WO2002011702A2 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Publications (1)

Publication Number Publication Date
AU2002229141A1 true AU2002229141A1 (en) 2002-02-18

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229141A Abandoned AU2002229141A1 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Country Status (30)

Country Link
US (2) US20030086972A1 (bg)
EP (1) EP1326587A2 (bg)
JP (1) JP2004505907A (bg)
KR (1) KR20030024844A (bg)
CN (1) CN1461212A (bg)
AP (1) AP2001002237A0 (bg)
AU (1) AU2002229141A1 (bg)
BG (1) BG107538A (bg)
BR (1) BR0113067A (bg)
CA (1) CA2418907A1 (bg)
DO (1) DOP2001000229A (bg)
EA (1) EA200300081A1 (bg)
EC (1) ECSP034455A (bg)
EE (1) EE200300055A (bg)
GT (1) GT200100161A (bg)
HR (1) HRP20030082A2 (bg)
HU (1) HUP0300722A2 (bg)
IL (1) IL154012A0 (bg)
IS (1) IS6686A (bg)
MA (1) MA26939A1 (bg)
MX (1) MXPA03001209A (bg)
NO (1) NO20030627L (bg)
OA (1) OA12365A (bg)
PA (1) PA8524901A1 (bg)
PE (1) PE20020307A1 (bg)
PL (1) PL360658A1 (bg)
SV (1) SV2002000586A (bg)
TN (1) TNSN01123A1 (bg)
UY (1) UY26876A1 (bg)
WO (1) WO2002011702A2 (bg)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
JP4100910B2 (ja) * 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
CN1596101A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 含有糖果组分的剂型
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2499882C (en) * 2002-09-28 2010-11-09 Mcneil-Ppc, Inc. Modified release dosage form with two cores
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
CA2601800C (en) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Oral drug delivery system
CA2600736A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
EP2012706A4 (en) * 2006-04-20 2013-02-13 Transport Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC METHOTREXATE RELEASE
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
WO2011055269A1 (en) * 2009-11-09 2011-05-12 Pfizer Inc. Delivery carrier
CN102791271B (zh) 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
JP6284163B2 (ja) * 2013-01-30 2018-02-28 デウン カンパニー，リミテッド 胃腸管内における傷の保護、止血、または癒着の防止のための医薬組成物
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN117597106A (zh) * 2021-05-28 2024-02-23 美国安进公司 阿普斯特配制品
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
WO2023063381A1 (ja) * 2021-10-14 2023-04-20 静岡県公立大学法人 粉末製剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
DK0758244T4 (da) * 1994-05-06 2008-06-16 Pfizer Doseringsformer af azithromycin med styret frigivelse
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
EA002481B1 (ru) * 1997-07-01 2002-06-27 Пфайзер Продактс Инк. Композиция на основе солюбилизированного сертралина
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2000021521A2 (en) * 1998-10-13 2000-04-20 Pfizer Products Inc. Sertraline oral concentrate
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GT200100039A (es) * 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
BR0317275A (pt) * 2002-12-11 2005-11-08 Pfizer Prod Inc Liberação controlada de uma substância ativa em um ambiente de gordura alta

Also Published As

Publication number Publication date
EE200300055A (et) 2004-12-15
WO2002011702A3 (en) 2002-11-28
IS6686A (is) 2003-01-16
US20030086972A1 (en) 2003-05-08
NO20030627L (no) 2003-04-08
BG107538A (bg) 2003-11-28
DOP2001000229A (es) 2002-09-30
MA26939A1 (fr) 2004-12-20
EP1326587A2 (en) 2003-07-16
ECSP034455A (es) 2003-03-10
MXPA03001209A (es) 2003-06-30
PE20020307A1 (es) 2002-04-23
CA2418907A1 (en) 2002-02-14
GT200100161A (es) 2002-03-22
WO2002011702A2 (en) 2002-02-14
HRP20030082A2 (en) 2003-04-30
JP2004505907A (ja) 2004-02-26
TNSN01123A1 (fr) 2005-11-10
HUP0300722A2 (hu) 2003-11-28
SV2002000586A (es) 2002-10-24
KR20030024844A (ko) 2003-03-26
PL360658A1 (en) 2004-09-20
PA8524901A1 (es) 2002-04-25
IL154012A0 (en) 2003-07-31
CN1461212A (zh) 2003-12-10
UY26876A1 (es) 2002-03-22
NO20030627D0 (no) 2003-02-07
BR0113067A (pt) 2003-07-01
US20040052845A1 (en) 2004-03-18
AP2001002237A0 (en) 2001-09-30
EA200300081A1 (ru) 2003-08-28
OA12365A (en) 2006-05-16

Similar Documents

Publication Publication Date Title
EP1242055B1 (en) Hydrogel-driven drug dosage form
US20030086972A1 (en) Hydrogel-driven drug dosage form
EP1027888B1 (en) Osmotic system for delivery of solid amorphous dispersions of drugs
US7550158B2 (en) Controlled release by extrusion of solid amorphous dispersions of drugs
NZ539915A (en) Controlled-release of an active substance into a high fat environment
US20030161882A1 (en) Osmotic delivery system
WO2007057762A2 (en) Osmotic bi-layer tablet